Efficacité de l’oxomémazine dans la toux : revue systématique de la littérature et méta-analyse des essais contrôlés randomisés (notice n° 1825549)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03330cam a2200325 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260329003542.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bacon, Trystan |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Efficacité de l’oxomémazine dans la toux : revue systématique de la littérature et méta-analyse des essais contrôlés randomisés |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 79 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Background: Cough is one of the most important symptoms in general practice. The medical prescription of oxomemazine represents a significant part of cough suppressant reimbursements in France. Objective: The aim of this study was to assess the efficacy of oxomemazine in cough. Methods: Systematic review and meta-analysis of randomized controlled trials according to the Rebuild the Evidence Base (REB) protocol. The protocol for this synthesis has been registered under the number PROSPERO CRD42022345496. We included RCTs comparing oxomemazine vs. placebo or active comparators in cough. We searched the following databases and registers to identify studies: Medline, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov. Results: No RCT was at low risk of bias thus no meta-analysis was conducted, according to REB protocol. Conclusion: There is no evidence of clinical efficacy of oxomemazine in cough. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Contexte : La toux est le signe fonctionnel le plus fréquent parmi les motifs de consultation de médecine générale. L’oxomémazine est la deuxième molécule la plus remboursée en France parmi celles ayant une autorisation de mise sur le marché dans le traitement symptomatique de la toux. Objectif(s) : L’objectif de cette étude est d’évaluer l’efficacité de l’oxomémazine dans la toux. Méthode : Revue systématique de la littérature avec méta-analyse des essais contrôlés randomisés (ECR) selon le protocole Rebuild the Evidence Base (REB). Les essais cliniques comparant l’efficacité de l’oxomémazine versus placebo ou comparateur actif dans la toux ont été recherchés. Les recherches ont été menées sur bases de données (Medline, Cochrane Central Register of Controlled Trials et Embase) et registres (plateforme internationale de registre des essais cliniques de l’Organisation mondiale de la santé et ClinicalTrials.gov). Résultat : Aucun ECR n’était à faible risque de biais. Aussi, aucune méta-analyse n’a été conduite, conformément au protocole REB. Conclusion : Cette revue systématique de la littérature conclut au manque d’évaluation de l’oxomémazine dans la toux et à l’absence de preuve d’efficacité selon la méthode REB. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antitussifs |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | médecine factuelle |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | oxomémazine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | revue systématique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | toux |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antitussive agents |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cough |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | evidence-based medicine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | oxomemazine |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Blanchard, Clara |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dubois, Estelle |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vaillant-Roussel, Hélène |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Boussageon, Rémy |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Médecine | 20 | 10 | 2025-01-14 | p. 469-475 | 1777-2044 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-medecine-2024-10-page-469?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-medecine-2024-10-page-469?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux